# Inhibition of VAP-1 by Caffeine in Healthy Human Volunteers Study

> **NCT02098785** · PHASE1 · WITHDRAWN · sponsor: **University of Birmingham**

## Conditions studied

- Liver Disease

## Interventions

- **DRUG:** Caffeine citrate

## Key facts

- **NCT ID:** NCT02098785
- **Lead sponsor:** University of Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-03
- **Primary completion:** 2018-09
- **Final completion:** 2018-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Local resource issue - never actually started post ethics approval.
- **Last updated:** 2018-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02098785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02098785, "Inhibition of VAP-1 by Caffeine in Healthy Human Volunteers Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02098785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*